April 01, 1989; 39 (4) Articles
Carbamazepine in Fabry's disease
Effective analgesia with dose‐dependent exacerbation of autonomic dysfunction
M. R. Filling-Katz, H. F. Merrick, J. K. Fink, R. B. Miles, J. Sokol, N. W. Barton
First published April 1, 1989, DOI: https://doi.org/10.1212/WNL.39.4.598
M. R. Filling-Katz
H. F. Merrick
J. K. Fink
R. B. Miles
J. Sokol
Carbamazepine in Fabry's disease
Effective analgesia with dose‐dependent exacerbation of autonomic dysfunction
M. R. Filling-Katz, H. F. Merrick, J. K. Fink, R. B. Miles, J. Sokol, N. W. Barton
Neurology Apr 1989, 39 (4) 598; DOI: 10.1212/WNL.39.4.598
Citation Manager Formats
Make Comment
See Comments

Abstract
Seven patients with Fabry's disease and severe pain received carbamazepine (CMZ). Five of 7 patients had moderate to complete relief baaed upon self-assessment of pain levels. Preexisting autonomic dysfunction was exacerbated by CMZ in 2. Complications encountered were ileus, urinary retention, and gastrointestinal disturbance. Although CMZ was useful in treatment of pain, caution should be employed in this disease.
- © 1989 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
No comments have been published for this article.
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Related Articles
- No related articles found.